@article{e875b230c58e49009712dce0914ef252,
title = "Exploring the role of ex vivo metabolism on blood and plasma measurements of oxytocin among women in the third stage of labour: A post hoc study",
abstract = "Aims: To examine the role of ex vivo oxytocin metabolism in post-dose peptide measurements. Methods: The stability of oxytocin (Study 1) and oxytocinase activity (Study 2) in late-stage pregnancy blood was quantified using liquid-chromatography tandem mass-spectrometry (LC–MS/MS) and a fluorogenic assay, respectively. Analyses were conducted using blood from pregnant women (>36 weeks gestation) evaluated in lithium heparin (LH), ethylenediaminetetraacetic acid (EDTA) and BD P100 blood collection tubes with or without protease inhibitors. In addition, plasma oxytocin concentrations following administration of oxytocin 240 IU inhaled, 5 IU intravenous or 10 IU intramuscular in women in third stage of labour (TSL) were analysed using enzyme-linked immunosorbent assay (ELISA) and LC–MS/MS to understand how quantified peptide concentrations differ between these analytical methods (Study 3). Results: Study 1: Oxytocin was stable in blood collected into EDTA tubes with or without protease inhibitors but not in LH tubes. Study 2: Blood collected into all EDTA-containing collection tubes led to near-complete inhibition of oxytocinase (≤100 min). In plasma, a 35% reduction in oxytocinase activity was observed in LH tubes with EDTA added. In plasma from late-stage pregnancy compared to nonpregnant participants, the oxytocinase activity was approximately 11-fold higher. Study 3: Plasma oxytocin concentrations from nonpregnant or women in TSL following exogenous oxytocin administration were ≤33 times higher when analysed using ELISA vs. LC–MS/MS methods. Conclusions: Collection of blood from late-stage pregnant women into tubes containing EDTA inhibits oxytocinase effectively stabilizing oxytocin, suggesting low concentrations of oxytocin after dose administration reflect rapid in vivo metabolism.",
keywords = "obstetric haemorrhage, oxytocin, oxytocinase",
author = "Oliver, {Victoria L.} and Sarah Siederer and Anthony Cahn and Katarzyna Gajewska-Knapik and Gibson, {Rachel A.} and Cleo Goodall and Carl Kirkpatrick and Jack Murray and Nguyen, {Tri Hung} and Ian Schneider and Pete Lambert and McIntosh, {Michelle P.} and Simon Parry",
note = "Funding Information: A.C., R.A.G. and S.S. are employees of and hold stocks in GSK. I.S. and S.P. were employed by GSK at the time of the study and hold stocks in GSK. M.P.M. declares having received research support from Janssen Pharmaceuticals, and grants/contracts from the Department of Education and Training, Victoria State Government (Smart Manufacturing and Technology Hub), the Victorian Medical Research Acceleration Fund, Department Jobs, Precincts and Regions, Victoria State Government (Clinical proof of concept for the inhaled oxytocin project), and the Medical Research Future Fund, Australian Government (Stroke – Prevention of Reperfusion Injury and Neuroinflammation – a Therapeutic Strategy: Medical Research Future Fund, Australian Government; Novel inhibitors of SARS coronaviruses targeting ACE2). M.P.M. also declared speaker honorarium for International Society for Aerosol Medicines Congress 2021, and is inventor on the patent method and formulation for oxytocin inhalation: McIntosh, M., D. Morton, T. Sou, L. Olerile and R. Prankerd (2014). US20140294969A1 ‐ WO2013/016754 A1 ‐ PCT/AU2011001430. These authors declare no other financial or nonfinancial relationships and activities. C.G., C.K., J.M., K.G.K., P.L., T.‐H.N. and V.L.O. declare no financial and nonfinancial relationships and activities and no conflicts of interest. Funding Information: GSK Plc funded this study (clinical study and effect of analytical method and analyses of oxytocin stability in collection tubes ‐ NCT02999100) and was involved in all stages of study conduct, including analysis of the data. GSK Plc also took in charge all costs associated with the development and publication of this manuscript. The study was also funded by the McCall MacBain Foundation (for the in vitro oxytocinase activity) Funding information post hoc Publisher Copyright: {\textcopyright} 2023 GSK. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.",
year = "2023",
month = dec,
doi = "10.1111/bcp.15865",
language = "English",
volume = "89",
pages = "3669--3680",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "12",
}